A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publically help companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of global pharmaceutical company based in japan is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with as much as $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.

The firm is currently looking for companies developing Therapeutics and Platform Technologies. The firm is looking for companies in this sector working with small molecules, vaccines and biotherapeutics. Indications of interested include nephrology, cardiovascular, immunology, inflammation, stroke, metabolic disease and the firm is especially interested in companies working with therapies for CNS disorders and orphan indications. Ideal companies will have assets either in preclinical stages or in Phase I of clinical trials.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office investment firm based in the Eastern United States specifically focuses on therapeutics for Cystic Fibrosis, including Adult Stem Cell Therapy. The firm manages an evergreen fund and can provide between $200K and $1M in equity per company. The firm has no specific requirement regarding where the company is located and is actively seeking new investment opportunities.

The firm is interested in all therapies for cystic fibrosis, including adult stem cell therapy. The firm looks for early-stage companies with products in pre-clinical or clinical development. Therapies for cystic fibrosis may include antibiotics, anti-inflammatories, airway surface hydrators, CFTR-modulating treatments, and others.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The operational and investment arm of a family office is looking to make equity investments into early stage companies and small mid-market growth companies ranging from $.5 to $1 million. The firm is very open to syndication particular with early stage deals and is capable of providing additional capital in follow on rounds when appropriate. The firm prefers to invest in companies located in the eastern United States and looks to make approximately 1-2 new investments per year.

The firm is looking for companies in the Medical Technology and Diagnostics space. Within these areas the firm is looking for 510k devices that are more technically based with a particular interest in hospital equipment and professional diagnostics. The firm is not interest in devices where the final consumer is the patient. The firm is looking to devices that improve the standard of care and is willing to invest in companies at all phases of development. The firm is generally open to all indications.

The firm looks for experienced management teams and looks to take a board seat following investment. The firm is willing to work with companies that have incomplete management teams and is looking for privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialist investor that is funded by private capital was founded in 2011 and has operations in Luxembourg, Belgium and USA. The firm exclusively focuses on investments in early-stage drug development companies targeting cancer therapies. The firm is most interested in companies from late seed stage to series A. The investment size will vary, and it can range from a few hundred thousand dollars up to a couple of million dollars. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently looking for new investments targeting the development of oncology therapies. The firm will not invest in medical device or diagnostics. The firm typically invests in companies with solid preclinical proof of concept (late preclinical stage/ pre-IND), and it will fund the companies at least up to human proof of concept (clinical phase Ib/ phase IIa). The firm prefers to invest in companies with small pipeline and a clear regulatory pathway. Historically, the firm was active in companies targeting immune therapy and tumor cell metabolism within the oncology field.

The firm primarily invests in private companies with experienced management team and breakthrough potential. The firm looks to be a lead investor and may take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund financed entirely by a Russian pharmaceutical company is looking to make investments ranging from $5-$15 million in companies in the life science space. The firm could make as many as 2-3 investment over the next 6-9 months and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The fund is currently looking for companies developing therapeutics and is open to both small molecules, biologics, and cell/gene therapy. The firm is more interested in companies working with single assets although they are also willing to consider platform technologies. Indications of interest include Oncology, Inflammation, Neurodegenerative diseases, Orphan genetic diseases, Critical care, Regenerative medicine and Cardiovascular. The firm looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The fund is looking for privately held companies and prefers companies with experienced management teams in place. The firm looks to act as a value-added investor through their strategic alignment with its parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A South Korean pharmaceutical company that specializes in Gastrointestinal, CNS, and Metabolic products is actively searching for promising therapeutic candidates under development around the world to incorporate into its pipeline. The company is flexible in terms of the structure, but mostly in-licensing or co-development. The company is interested in world wide/major territories such as the US, EU, APAC, and East Asia.

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. The company is most interested in neurology, hepatology, and gastroenterology. However, the firm is also interested in other therapeutic areas that address large unmet medical needs. The company will look at both small molecules and biologics and will consider only NCE or NCE-like molecules (such as repositioning molecule, new indication, etc). The company prefers assets in phase I, II, or IND-ready. However, the company will also look at assets in phase III and NDA stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com